Quick Answer
Moleculin Biotech, Inc. reported R&D Expense of $15.89 million for fiscal year 2025.
Moleculin Biotech, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $15.89M | -10.4% |
| 2024 | $17.73M | -9.0% |
| 2023 | $19.49M | +2.7% |
| 2022 | $18.97M | +31.6% |
| 2021 | $14.42M | +13.0% |
| 2020 | $12.76M | +15.8% |
| 2019 | $11.01M | +13.2% |
| 2018 | $9.73M | +114.0% |
| 2017 | $4.54M | +203.8% |
| 2016 | $1.50M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.74M | -24.2% | +3.8% |
| June 30, 2025 | $3.60M | -12.0% | +4.8% |
| March 31, 2025 | $3.44M | -19.2% | -30.4% |
| September 30, 2024 | $4.93M | +50.4% | +20.6% |
| June 30, 2024 | $4.09M | +5.2% | -3.8% |
| March 31, 2024 | $4.25M | -25.2% | +29.6% |
| September 30, 2023 | $3.28M | -45.0% | -15.6% |
| June 30, 2023 | $3.89M | -7.5% | -31.6% |
- Moleculin Biotech, Inc. showed a decrease of -10.4% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Moleculin Biotech, Inc.’s r&d expense has grown by 962.2% (from $1.50 million to $15.89 million).
- The most recent figure is from Moleculin Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: